



“Providing an opportunity for multiple myeloma patients and their loved ones to come together to exchange information for mutual support, comfort, and friendship”

Meeting: Tuesday November 21, 2017 3:30pm – 5:30pm
451 Junction Road
UW West Clinic Room 1287
Enter the clinic... proceed left past the vending area... turn left again and conf. room 1287 is the last one on the left.

Information: Jayne Schwartz 608- 244-2120 Madison Multiple Myeloma Support Group website
schwartzdon@sbcglobal.net madisonmultiplemyeloma.org

Mailing Address: Wisconsin Multiple Myeloma Support Group
3309 Chicago Avenue
Madison, WI 53714-1815

More Information:
International Myeloma Foundation (IMF) Multiple Myeloma Research Foundation (MMRF)
Phone: 800 - 452 - 2873 203 - 972 - 1250
Email: TheIMF@myeloma.org info@themmrf.org
Website: www.myeloma.org www.multiplemyeloma.org

The Multiple Myeloma Patient and Caregiver Symposium Saturday, November 18, 2017.
You still have time to register! Conference is free to all attendees.

The Country Springs Hotel

www.countryspringshotel.com
2810 Golf Road
Pewaukee, WI 53072

Saturday November 18, 2017 7:30 am – 3:00 pm

An Educational Conference for Patients, Caregivers and Healthcare Professionals

Register at: mcw.edu/Register-2017-MM-Symposium

The Trillium presentation was a huge success! There was standing room only with clearly more than 200+ attendees. Nine researchers, scientists and doctors each gave a 15 minute presentation on a wide range of topics - Clinical trials, Mind-Body Influences, Immunotherapy, Predicting Myeloma drug responses, Mobilizing the Immune System, MRD, Synstatin to suppress Myeloma, Microbiome and Novel Cellular Therapies. It is amazing the work that is being accomplished with the help of the Trillium fund.

Consider the Trillium Fund for your year-end charity donation. Information on how to contribute is always at the end of each newsletter. We are making a difference.

Copay Assistance Programs

As you may be aware, as of October 18, 2017, there are no copay assistance plans open to new myeloma applicants and apparently aid has been suspended to those currently enrolled in programs. Within the last month, Patient Advocate Foundation, Healthwell Foundation, Leukemia & Lymphoma Society, and CancerCare have closed joining Good Days from the Chronic Disease Fund and the Patient Access Network Foundation which suspended their services earlier in the year. *We thank support group leader, Jerry Landy for putting together and sharing this information.*

The IMF is diligently staying on top of this and will keep our website up to date: <https://www.myeloma.org/article/co-pay-assistance-programs-update>

For now, patients are advised to contact the financial aid programs of the drug manufacturers directly.

Celgene's (*Thalomid, Revlimid, & Pomalyst*) patient support web portal: <https://www.celgenepatientsupport.com/>

Takeda Financial Aid

Ninlaro 1Point Program: <https://www.ninlaro.com/cost>

Velcade Support: <http://www.velcade.com/paying-for-treatment/>

Amgen Kyprolis

Amgen Assist 360 Program: <http://www.amgenassist360.com/patient/kyprolis-cost-nurse-ambassador-assistance/>

Janssen Darzalex

Janssen CarePath Program: <https://www.darzalexhcp.com/cost-support/janssen-carepath#affordability>

If you have additional questions, please contact the IMF's Infoline team: 800-452-2873 (Monday-Friday 9:00 am – 4:00 pm Pacific) or by e-mail at: Infoline@myeloma.org.

IV Cinvanti Approved to Treat Chemotherapy-Induced Nausea and Vomiting by Brielle Urcioli

Published November 09, 2017

Another agent – Cinvanti (aprepitant) injectable emulsion – was approved by the Food and Drug Administration (FDA) to treat chemotherapy-induced nausea/vomiting (CINV).

The drug will be used in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting.

“CINV remains a high unmet medical need in the oncology community, and five full days of CINV coverage continues to be our goal. This provides a large opportunity for CINVANTI to help more patients avoid CINV and adhere to their chemotherapy regimens,” said Jeffrey F. Patton, M.D., Chief Executive Officer of Tennessee Oncology in a statement.

Cinvanti is the first-approved neurokinin-1 (NK1) receptor antagonist that does not have polysorbate 80, which frequently causes allergic reactions that may make patients unable to take another anti-emetic.

“Aprepitant has long been the standard in the NK1 class and it remains the only single-agent NK1 with proven efficacy in preventing CINV in both the acute and delayed phases after treatment. Because CINVANTI is a novel, polysorbate 80-free IV formulation of aprepitant, it enables physicians to provide patients with standard-of-care efficacy without the potential risk of polysorbate 80-related adverse events, such as infusion-site reactions,” said Rudolph M. Navari, M.D., Ph.D., University of Alabama, Birmingham School of Medicine, Director, Cancer Care Program, Division of Hematology Oncology.

The commercial launch of the drug is planned for January 2018, according to Heron Therapeutics.

“Help for Cancer Caregivers” from CancerCare E-News for November 2017

Cancer profoundly affects family members, friends and others who are close to a person diagnosed with cancer. It can be especially difficult and overwhelming for the primary caregiver, who is often tasked with coordinating help from multiple people.

To help caregivers organize a network of support, *CancerCare* offers a simple online tool called **My Cancer Circle** - a free, private support community for caregivers of people facing cancer.

Create Your Community

IMF Info Line – If you or someone you care for has myeloma, you have questions. Probably, lots of them. You can search the Internet all you want, but other than asking your doctor, there is no better way to get your questions answered than to call the IMF Info Line. Missy, Judy and Paul know their stuff and they want to share what they know with you. Just ask anyone who has called the IMF Info Line. Patients or caregivers are welcome to contact the Info Line staffed by trained specialists at 800-452-CURE (800-452-2873). The Info Line is staffed between 9am and 4pm Pacific Time, 11am to 6pm Central time or infoline@myeloma.org.

The Trillium Fund was established by our founding support group members to facilitate Multiple Myeloma research here in Madison at the Wisconsin Institute of Medical Research. If you or your family wish to donate or send a memorial to this program, checks can be made payable to the “UW Foundation – Trillium Fund”.

Katie Williquette

UW Carbone Cancer Center

600 Highland Avenue, K4/658

Madison, WI 53792-6164

(608) 263-0160

kwilliquette@uwcarbone.wisc.edu